Founded in 2014, Kind Pharmaceuticals Co., Ltd. is a global biotechnology company focused on pan-anemia disorders and oncology. Upholding the philosophy of “Cherish Humanity, Respect Science, Benefit Patients”, the Company is committed to addressing unmet global clinical needs by developing scientifically rigorous, clinically transformative innovative therapies. The Company’s clinical-stage pipeline includes AND017, a novel small-molecule HIF pathway stabilizer for the treatment of a broad range of anemias, and AND019, a next-generation oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer. Andao also advances four preclinical candidates covering multiple oncology and reno-cardiology indications. In addition, the Company has established its proprietary RICIN ADC platform to overcome the key limitations of conventional ADC technologies.